Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
EJHaem ; 4(3): 719-722, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37601879

ABSTRACT

Long-term follow-up of multiple myeloma (MM) clinical trials are needed to assess long-term outcomes. We aimed to investigate the length of follow-up of all phase III MM clinical trials. Median follow-up duration of clinical trials of newly diagnosed MM was longer when compared to relapsed/refractory MM clinical trials (42.7 vs. 20.5 months, respectively). The follow-up duration of phase III clinical trials in MM is relatively short when compared to the improved outcomes in the current era. Efforts should be made to facilitate long-term clinical trials follow-up and/or publication of results of updated results.

2.
Transplant Cell Ther ; 28(9): 572-580, 2022 09.
Article in English | MEDLINE | ID: mdl-35750284

ABSTRACT

The use of autologous stem cell transplantation (ASCT) in multiple myeloma (MM) is the standard of care in patients who are deemed transplantation eligible. Novel therapies, namely immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, have revolutionized the treatment algorithm for MM but have not yet resulted in a cure. To achieve long-lasting disease control in MM, a high-dose conditioning regimen followed by ASCT continues to be an essential part of the management of transplantation-eligible patients with MM. High-dose (or conditioning) regimens are preparative chemotherapy-based regimens used before ASCT. High-dose melphalan is the most commonly used regimen in MM treatment. This clinical review provides an evidence-based summary to guide practicing hematologists/oncologists in the various high-dose regimens used before ASCT in MM treatment. We highlight the use of single-agent melphalan along with various combination-based high-dose regimens with their clinical efficacy. Various dosing schedules and modifications, timing of administration, and novel drugs-based combination regimens are discussed.


Subject(s)
Hematopoietic Stem Cell Transplantation , Multiple Myeloma , Humans , Melphalan , Transplantation Conditioning , Transplantation, Autologous
SELECTION OF CITATIONS
SEARCH DETAIL
...